» Articles » PMID: 27978939

Should HIV Testing for All Pregnant Women Continue? Cost-effectiveness of Universal Antenatal Testing Compared to Focused Approaches Across High to Very Low HIV Prevalence Settings

Overview
Journal J Int AIDS Soc
Date 2016 Dec 17
PMID 27978939
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: HIV testing is the entry point for the elimination of mother-to-child transmission of HIV. Decreasing external funding for the HIV response in some low- and middle-income countries has triggered the question of whether a focused approach to HIV testing targeting pregnant women in high-burden areas should be considered. This study aimed at determining and comparing the cost-effectiveness of universal and focused HIV testing approaches for pregnant women across high to very low HIV prevalence settings.

Methods: We conducted a modelling analysis on health and cost outcomes of HIV testing for pregnant women using four country-based case scenarios (Namibia, Kenya, Haiti and Viet Nam) to illustrate high, intermediate, low and very low HIV prevalence settings. We used subnational prevalence data to divide each country into high-, medium- and low-burden areas, and modelled different antenatal and testing coverage in each.

Results: When HIV testing services were only focused in high-burden areas within a country, mother-to-child transmission rates remained high ranging from 18 to 23%, resulting in a 25 to 69% increase in new paediatric HIV infections and increased future treatment costs for children. Universal HIV testing was found to be dominant (i.e. more QALYs gained with less cost) compared to focused approaches in the Namibia, Kenya and Haiti scenarios. The universal approach was also very cost-effective compared to focused approaches, with $ 125 per quality-adjusted life years gained in the Viet Nam-based scenario of very low HIV prevalence. Sensitivity analysis further supported the findings.

Conclusions: Universal approach to antenatal HIV testing achieves the best health outcomes and is cost-saving or cost-effective in the long term across the range of HIV prevalence settings. It is further a prerequisite for quality maternal and child healthcare and for the elimination of mother-to-child transmission of HIV.

Citing Articles

The urgency of now to end HIV vertical transmission for pregnant and breastfeeding women and their children in Asia and the Pacific.

Kelly-Hanku A, Songtaweesin W, Palmares M, Bartlett A, Gare J, Sta Maria M Lancet Reg Health West Pac. 2025; 53():101248.

PMID: 39802203 PMC: 11724994. DOI: 10.1016/j.lanwpc.2024.101248.


Growth Trajectories Over the First Year of Life Among Early-Treated Infants with Human Immunodeficiency Virus and Infants Who are Human Immunodeficiency Virus-Exposed Uninfected.

Barrios-Tascon A, Strehlau R, Patel F, Burke M, Shiau S, Shen Y J Pediatr. 2024; 270:114018.

PMID: 38508485 PMC: 11176027. DOI: 10.1016/j.jpeds.2024.114018.


The End Is in Sight: Current Strategies for the Elimination of HIV Vertical Transmission.

Yang L, Cambou M, Nielsen-Saines K Curr HIV/AIDS Rep. 2023; 20(3):121-130.

PMID: 36971951 PMC: 10239317. DOI: 10.1007/s11904-023-00655-z.


Health and medical professionals' antenatal HIV testing practices and perceived barriers to routine testing in Tasmania, Australia: a qualitative study.

Ayton J, Bennett-Daly G, Nguyen A, Owen L BMJ Open. 2023; 13(3):e069819.

PMID: 36878657 PMC: 9990605. DOI: 10.1136/bmjopen-2022-069819.


Economic costs and cost-effectiveness of conditional cash transfers for the uptake of services for the prevention of vertical HIV transmissions in a resource-limited setting.

Masiano S, Kawende B, Ravelomanana N, Green T, Dahman B, Thirumurthy H Soc Sci Med. 2023; 320:115684.

PMID: 36696797 PMC: 9975037. DOI: 10.1016/j.socscimed.2023.115684.


References
1.
Walensky R, Ross E, Kumarasamy N, Wood R, Noubary F, Paltiel A . Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. N Engl J Med. 2013; 369(18):1715-25. PMC: 3913536. DOI: 10.1056/NEJMsa1214720. View

2.
Ishikawa N, Shimbo T, Miyano S, Sikazwe I, Mwango A, Ghidinelli M . Health outcomes and cost impact of the new WHO 2013 guidelines on prevention of mother-to-child transmission of HIV in Zambia. PLoS One. 2014; 9(3):e90991. PMC: 3946295. DOI: 10.1371/journal.pone.0090991. View

3.
Gopalappa C, Stover J, Shaffer N, Mahy M . The costs and benefits of Option B+ for the prevention of mother-to-child transmission of HIV. AIDS. 2014; 28 Suppl 1:S5-14. DOI: 10.1097/QAD.0000000000000083. View

4.
Laufer F, Warren B, Pulver W, Smith L, Wright R, Birkhead G . Return on Investment From Expenditures Incurred to Eliminate Mother-To-Child Transmission Among HIV-Infected Women in New York State: 1998-2013. J Acquir Immune Defic Syndr. 2016; 71(5):558-62. DOI: 10.1097/QAI.0000000000000899. View

5.
Soorapanth S, Sansom S, Bulterys M, Besser M, Theron G, Fowler M . Cost-effectiveness of HIV rescreening during late pregnancy to prevent mother-to-child HIV transmission in South Africa and other resource-limited settings. J Acquir Immune Defic Syndr. 2006; 42(2):213-21. DOI: 10.1097/01.qai.0000214812.72916.bc. View